ERBB2 and ductal breast carcinoma in situ: In Von Minckwitz et al.’s analysis of 158 HER2-positive breast cancer patients treated by NAC combined with trastuzumab [16], 50.8% of the samples in which a DCIS component was associated with invasive carcinoma showed a complete eradication of DCIS after NAC.